Recce Pharmaceuticals (RCE.AX) Stock Price

Recce Pharmaceuticals Price

ASX·CLOSED
0.37
​
Market closed

Over the last 12 years Recce Pharmaceuticals grew revenue by 127.7% annually, reaching 7.51 M AUD. For Recce Pharmaceuticals, the net margin of -285.4% is up versus -825.3% a few years ago.

Recce Pharmaceuticals stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals business model & stock analysis

Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes.

Frequently asked questions about Recce Pharmaceuticals

Converted at the current exchange rate, the Recce Pharmaceuticals share trades at 0.23 EUR (0.37 AUD).

The Recce Pharmaceuticals share (RCE.AX) is listed on 3 stock exchanges, including: ASX (RCE.AX), Frankfurt (R9Q.F), München (R9Q.MU).

The revenue cannot currently be calculated for Recce Pharmaceuticals.

The profit of Recce Pharmaceuticals is -14.96 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Recce Pharmaceuticals is currently -7.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Recce Pharmaceuticals stock.

The P/S cannot be calculated for Recce Pharmaceuticals currently.

The Eulerpool Quality Score for Recce Pharmaceuticals is 6/10.

The ISIN of Recce Pharmaceuticals is AU000000RCE5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Recce Pharmaceuticals is A2ADQM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Recce Pharmaceuticals is RCE.AX. The ticker symbol is used to trade Recce Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
0.31 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website recce.com.au
Country
Australia
Currency
AUD
Initial public offering
Jan 15, 2016
ISIN
AU000000RCE5
Cusip
Q8052V103
Market capitalization
107.00 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-4.11
P/Ee 2028
-4.09
P/Se
31.60
EV/EBIT
—
P/B Ratio
10.63
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
238.19 %
Last updated Nov 18, 2026, 8:36 AM

Recce Pharmaceuticals Peer Group

Recce Pharmaceuticals Ticker

ASX · RCE.AXFRANKFURT · R9Q.FMUNICH · R9Q.MU

Recce Pharmaceuticals FIGI

RCE:AU · BBG009XWNPF6RCE:AT · BBG009XWNPG5RCE:AH · BBG009XWNPL9RECEF:US · BBG00RHNFXV8RECEF:PQ · BBG00RHNFY82RECEF:UV · BBG00RHNFY91R9Q:GR · BBG00TX25HN7R9Q:GF · BBG00TX25HQ4R9Q:GS · BBG00TX25HV8R9Q:GM · BBG00TX25HW7R9Q:GB · BBG00TX25HX6RCEEUR:XS · BBG00TYNXKG0